Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
||
| Line 24: | Line 24: | ||
|- | |- | ||
|[https://doi.org/10.1111/bjh.14966 Nozza et al. 2017] | |[https://doi.org/10.1111/bjh.14966 Nozza et al. 2017] | ||
| − | |style="background-color:#ffffbe"|Phase 2, | + | |style="background-color:#ffffbe"|Phase 2, fewer than 20 pts |
|- | |- | ||
|} | |} | ||
Revision as of 06:50, 18 July 2023
Section editor transclusions POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
Lenalidomide & Dexamethasone (Rd)
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
Regimen
| Study | Evidence |
|---|---|
| Nozza et al. 2017 | Phase 2, fewer than 20 pts |
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
28-day cycle for at least 6 cycles
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains dosing details in manuscript PubMed